...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR 2018

I wonder, with ABBVie and others in this area it is a busy field. That could be very good for profile with investors. The companies in this field have big money to spend.

I feel the challenge is what does Don have to attract a $10 million investor to Zenith. There is no recent info on the zen3694 trial and the results to date are very mixed.

I would assume that raising money for RVX is by far Don's top priority and that seems to be dragging, to say the least.

Perhaps a good story will immerge on the science side to give Don something to sell?

My personal feeling is that the situation is not well organized at Zenith Epi. Hopefully the scientists are still beavering away but at some point they will need $.

Toinv

Share
New Message
Please login to post a reply